Ruxolitinib in severe COVID-19: Results of a multicenter, prospective, single arm, open-label clinical study to investigate the efficacy and safety of ruxolitinib in patients with COVID-19 and severe acute respiratory syndrome

Rev Fac Cien Med Univ Nac Cordoba · 2021 · PMC8760921 · PMID 34617700

Europe PMC DOI

hedged sentence

0.2400

closest p · 4.8× alpha

0.2400

boldest claim

The sentences

showed a trendp = 0.24not close (p > 0.1)

Most available literature regarding infections refers to chronic hematological diseases 31 . CONCLUSION Ruxolitinib failed to significantly reduce the proportion of COVID-19 pneumonia patients requiring ICU admission and MV, but once admitted, the mortality rate showed a trend to be lower (p = 0.24).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.